Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
...Treatment...
...dation 1.1Selection of initial treatment opti...
...ndation 1.2All treatment decisions shou...
...1.3Patients should be assessed for SST...
...II. Systemic Therapy...
...First-...
Recommendation 2.1SSAs (octreotide or lanreot...
...n 2.2In the less common circumstance of patients...
...Second- o...
...ommendation 2.3Peptide receptor radionuclide the...
...mmendation 2.4Everolimus is recommended for pat...
...III. Systemic Th...
...ommendation 3.1SSAs (octreotide or lanreotide) ar...
...3.2Chemotherapy (e.g., capecitabine and temozol...
...mendation 3.3Chemotherapy (e.g., CAPTEM),...
...Second- or Later-l...
...3.4PRRT for SSTR-positive tumors,...
...IV. Systemic Therap...
...endation 4.1The range of systemic opti...
...assification and Grading Criteria for We...
Figure 1. Systemic Therapy for Tumor Control in We...
...CO believes that cancer clinical trials are...